Literature DB >> 17895239

Prostaglandin E2 activates HPK1 kinase activity via a PKA-dependent pathway.

Sansana Sawasdikosol1, Saiju Pyarajan, Saba Alzabin, Gabriel Matejovic, Steven J Burakoff.   

Abstract

Hematopoietic progenitor kinase 1 (HPK1) is a hematopoietic cell-restricted member of the Ste20 serine/threonine kinase super family. We recently reported that the immunosuppressive eicosanoid, prostaglandin E(2) (PGE(2)), is capable of activating HPK1 in T cells. In this report, we demonstrate that unlike the TCR-induced activation of HPK1 kinase activity, the induction of HPK1 catalytic activity by PGE(2) does not require the presence of phosphotyrosine-based signaling molecules such as Lck, ZAP-70, SLP-76, and Lat. Nor does the PGE(2)-induced HPK1 activation require the intermolecular interaction between its proline-rich regions and the SH3 domain-containing adaptor proteins, as required by the signaling from the TCR to HPK1. Instead, our study reveals that PGE(2) signal to HPK1 via a 3' -5 '-cyclic adenosine monophosphate-regulated, PKA-dependent pathway. Consistent with this observation, changing the serine 171 residue that forms the optimal PKA phosphorylation site within the "activation loop" of HPK1 to alanine completely prevents this mutant from responding to PGE(2)-generated stimulation signals. Moreover, the inability of HPK1 to respond to PGE(2) stimulation in PKA-deficient S49 cells further supports the importance of PKA in this signaling pathway. We speculate that this unique signaling pathway enables PGE(2) signals to engage a proven negative regulator of TCR signal transduction pathway and uses it to inhibit T cell activation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17895239     DOI: 10.1074/jbc.M707425200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  14 in total

Review 1.  HPK1 as a novel target for cancer immunotherapy.

Authors:  Sansana Sawasdikosol; Renyuan Zha; Boyu Yang; Steven Burakoff
Journal:  Immunol Res       Date:  2012-12       Impact factor: 2.829

2.  NFAT and CREB regulate Kaposi's sarcoma-associated herpesvirus-induced cyclooxygenase 2 (COX-2).

Authors:  Neelam Sharma-Walia; Arun George Paul; Kinjan Patel; Karthic Chandran; Waseem Ahmad; Bala Chandran
Journal:  J Virol       Date:  2010-10-13       Impact factor: 5.103

3.  Kaposi's sarcoma associated herpes virus (KSHV) induced COX-2: a key factor in latency, inflammation, angiogenesis, cell survival and invasion.

Authors:  Neelam Sharma-Walia; Arun George Paul; Virginie Bottero; Sathish Sadagopan; Mohanan Valiya Veettil; Nagaraj Kerur; Bala Chandran
Journal:  PLoS Pathog       Date:  2010-02-12       Impact factor: 6.823

Review 4.  The expanding role for small molecules in immuno-oncology.

Authors:  Rienk Offringa; Lisa Kötzner; Bayard Huck; Klaus Urbahns
Journal:  Nat Rev Drug Discov       Date:  2022-08-18       Impact factor: 112.288

5.  Proteasome-mediated degradation and functions of hematopoietic progenitor kinase 1 in pancreatic cancer.

Authors:  Hua Wang; Xianzhou Song; Craig Logsdon; Guisheng Zhou; Douglas B Evans; James L Abbruzzese; Stanley R Hamilton; Tse-Hua Tan; Huamin Wang
Journal:  Cancer Res       Date:  2009-01-13       Impact factor: 12.701

6.  The CUL7/F-box and WD repeat domain containing 8 (CUL7/Fbxw8) ubiquitin ligase promotes degradation of hematopoietic progenitor kinase 1.

Authors:  Hua Wang; Yue Chen; Ping Lin; Lei Li; Guisheng Zhou; Guangchao Liu; Craig Logsdon; Jianping Jin; James L Abbruzzese; Tse-Hua Tan; Huamin Wang
Journal:  J Biol Chem       Date:  2013-12-20       Impact factor: 5.157

7.  Discovery of Diaminopyrimidine Carboxamide HPK1 Inhibitors as Preclinical Immunotherapy Tool Compounds.

Authors:  Brandon A Vara; Samuel M Levi; Abdelghani Achab; David A Candito; Xavier Fradera; Charles A Lesburg; Shuhei Kawamura; Brian M Lacey; Jongwon Lim; Joey L Methot; Zangwei Xu; Haiyan Xu; Dustin M Smith; Jennifer A Piesvaux; J Richard Miller; Mark Bittinger; Sheila H Ranganath; David J Bennett; Erin F DiMauro; Alexander Pasternak
Journal:  ACS Med Chem Lett       Date:  2021-03-19       Impact factor: 4.345

8.  Critical role of kinase activity of hematopoietic progenitor kinase 1 in anti-tumor immune surveillance.

Authors:  Jinqi Liu; Joshua Curtin; Dan You; Stephen Hillerman; Bifang Li-Wang; Rukiye Eraslan; Jenny Xie; Jesse Swanson; Ching-Ping Ho; Simone Oppenheimer; Bethanne M Warrack; Colleen A McNaney; David M Nelson; Jordan Blum; Taeg Kim; Mark Fereshteh; Michael Reily; Petia Shipkova; Anwar Murtaza; Miguel Sanjuan; John T Hunt; Luisa Salter-Cid
Journal:  PLoS One       Date:  2019-03-26       Impact factor: 3.240

9.  Hematopoietic progenitor kinase 1 is a critical component of prostaglandin E2-mediated suppression of the anti-tumor immune response.

Authors:  Saba Alzabin; Saiju Pyarajan; Herman Yee; Friedemann Kiefer; Akira Suzuki; Steven Burakoff; Sansana Sawasdikosol
Journal:  Cancer Immunol Immunother       Date:  2009-09-29       Impact factor: 6.968

Review 10.  A perspective on HPK1 as a novel immuno-oncology drug target.

Authors:  Sansana Sawasdikosol; Steven Burakoff
Journal:  Elife       Date:  2020-09-08       Impact factor: 8.140

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.